SCHEMBL12794869

SCHEMBL12794869

CCOC(=O)c1cnc(Cl)c2ncn(CCO[Si](C)(C)C(C)(C)C)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 3/20 0.35
MEN1 O00255 2/20 0.35
LMNA P02545 3/20 0.35
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
PKM P14618 1/20 0.34
DGAT1 O75907 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPK10 P53779 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL986150 0.94 DUT (0.38) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL12794868 0.88 RAB9A (0.38) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL986279 0.82 RAB9A (0.39) ALDH1A1KDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4791366 0.78 BAZ2B (0.44) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL986392 0.70 NPC1 (0.43) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL12794865 0.70 KDM4E (0.44) KMT2AALDH1A1KDM4EMEN1MAPK1
SCHEMBL987310 0.70 NPC1 (0.44) ALDH1A1KDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL984958 0.69 KDM4E (0.46) KMT2AALDH1A1KDM4EMEN1MAPK1
SCHEMBL12794872 0.69 RAB9A (0.43) KMT2AALDH1A1KDM4EMEN1MAPK1
SCHEMBL986685 0.69 PDE5A (0.42) KMT2AKDM4EMEN1MAPK1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410065-B2 Macrolides and their use BASILEA PHARMACEUTICA AG (CH) 2013-04-02 US disclosed
US-20110053876-A1 MACROLIDES AND THEIR USE BASILEA PHARMACEUTICA AG (CH) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053876-A1 MACROLIDES AND THEIR USE PDE4A, PDE12, PDE4B KMT2A 2755/4885ALDH1A1 1654/4885KDM4E 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.